Literature DB >> 29258873

Perimenopausal bone histomorphometry before and after menopause.

Robert R Recker1, Joan M Lappe2, Michael Davies3, Donald Kimmel4.   

Abstract

Investigators and clinicians have had few normal bone histomorphometry data available to compare with those found in diseased patients, or in the results of treatments. The Goals and Objectives of this work are two-fold: 1. to present static and dynamic bone histomorphometry data from transilial bone biopsies performed on 76 healthy, premenopausal women. 2. To present paired static and dynamic bone histomorphometry data from bone biopsies on a subset (N=51 pairs) of these same healthy women whose biopsies were repeated 12months after their last menses. Statistical comparisons between the pre- and postmenopausal data are presented. These data will shrink this important gap, both for clinicians and investigators. We enrolled 76 healthy, premenopausal women over age 46, performed transilial bone biopsies after tetracycline labeling, and during a period of 9.5years, we re-biopsied 51 of them who passed through menopause and remained healthy the entire time. We also obtained serum biochemical measurements, and serial DXA exams during the period of observation. The dynamic bone histomorphometry demonstrated a doubling of bone remodeling, and increases in serum bone markers at the time of the second biopsy. Lumbar spine bone density also declined, and there were significant correlations between serum markers and histomorphometry variables. The data demonstrate that healthy menopause results in an important increase in bone remodeling, and a loss of bone density. We do not fully understand the mechanisms of these transmenopausal changes, but the data provide some clues that are helpful.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biopsy; Bone; Histomorphometry; Menopause; Normals; Transiliac

Mesh:

Substances:

Year:  2017        PMID: 29258873     DOI: 10.1016/j.bone.2017.12.016

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Reference Intervals for Bone Histomorphometric Measurements Based on Data from Healthy Premenopausal Women.

Authors:  Shijing Qiu; George Divine; Elizabeth Warner; Sudhaker D Rao
Journal:  Calcif Tissue Int       Date:  2020-08-20       Impact factor: 4.333

2.  The influence of CT and dual-energy X-ray absorptiometry (DXA) bone density on quantitative [18F] sodium fluoride PET.

Authors:  Inderbir S Jassel; Musib Siddique; Michelle L Frost; Amelia E B Moore; Tanuj Puri; Glen M Blake
Journal:  Quant Imaging Med Surg       Date:  2019-02

3.  Generalized Uncoupled Bone Remodeling Associated With Delayed Healing of Fatigue Fractures.

Authors:  Xiaoyu Tong; Mikael J Turunen; Inari S Burton; Heikki Kröger
Journal:  JBMR Plus       Date:  2022-01-19

4.  Association between bone mineral metabolism and vascular calcification in end-stage renal disease.

Authors:  Louise Aaltonen; Niina Koivuviita; Marko Seppänen; Heikki Kröger; Xiaoyu Tong; Eliisa Löyttyniemi; Kaj Metsärinne
Journal:  BMC Nephrol       Date:  2022-01-03       Impact factor: 2.388

5.  Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells.

Authors:  Jin Hyung Kim; Seung-Taek Lee
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

6.  Establishment and evaluation of a novel mouse model of peri/postmenopausal depression.

Authors:  Ling Zhang; Lu-Lu Cao; Dan-Dan Yang; Jian-Hua Ding; Xu-Dong Guo; Teng-Fei Xue; Xiao-Jie Zhao; Xiu-Lan Sun
Journal:  Heliyon       Date:  2019-02-04

7.  Bone Histomorphometry and 18F-Sodium Fluoride Positron Emission Tomography Imaging: Comparison Between only Bone Turnover-based and Unified TMV-based Classification of Renal Osteodystrophy.

Authors:  Louise Aaltonen; Niina Koivuviita; Marko Seppänen; Inari S Burton; Heikki Kröger; Eliisa Löyttyniemi; Kaj Metsärinne
Journal:  Calcif Tissue Int       Date:  2021-06-17       Impact factor: 4.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.